Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
25 articles scientifiques publiés — un praticien à la pointe de la recherche
Expérience confirmée
20 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
20ans d'exercice (thèse 2006)
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Genetic variability of pulmonary innate immunity and risk for infection in cystic fibrosis disease
Direction : Jean-Paul Mira
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Incident Cheyne-Stokes respiration occurring in CPAP-treated patients and cardiovascular risk: a 2-years prospective follow-up (The Alertapnee study)
2025ArticleRespiratory Research
Continuous positive airway pressure treatment for obstructive sleep apnea, hospitalizations, and related costs in the French National Healthcare Insurance database
2024ArticleRespiratory Medicine and Research
National Implementation of CPAP Telemonitoring and a Pay-for-performance Scheme for Homecare Providers in France Leads to Prioritisation of Resources to Individuals with Low Therapy Adherence: The IMPACT-PAP Cohort Study
2024ArticleArchivos de Bronconeumología
The PAP-RES algorithm: Defining who, why and how to use positive airway pressure therapy for OSA
2024ArticleSleep Medicine Reviews
Prevalence of sleep apnoea in patients with type 1 diabetes and its association with comorbidities and diabetic complications: A French nationwide prospective study
2023ArticleDiabetes, Obesity and Metabolism
CPAP telemonitoring can track Cheyne–Stokes respiration and detect serious cardiac events: The AlertApnée Study
2022ArticleRespirology
Determinants of mortality for adults with cystic fibrosis admitted in Intensive Care Unit: a multicenter study.
2006ArticleRespiratory Research
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP CUP SITE COCHIN PORT ROYAL
27 R DU FAUBOURG SAINT JACQUES, 75679 PARIS CEDEX 14
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Critical care medicine · 2004
The European respiratory journal · 2018
The COPD Patient Management European Trial (COMET) investigated the efficacy and safety of a home-based COPD disease management intervention for severe COPD patients.The study was an international open-design clinical trial in COPD patients (forced expiratory volume in 1 s <50% of predicted value) randomised 1:1 to the disease management intervention or to the usual management practices at the study centre. The disease management intervention included a self-management programme, home telemonitoring, care coordination and medical management. The primary end-point was the number of unplanned all-cause hospitalisation days in the intention-to-treat (ITT) population. Secondary end-points included acute care hospitalisation days, BODE (body mass index, airflow obstruction, dyspnoea and exercise) index and exacerbations. Safety end-points included adverse events and deaths.For the 157 (disease management) and 162 (usual management) patients eligible for ITT analyses, all-cause hospitalisation days per year (mean±sd) were 17.4±35.4 and 22.6±41.8, respectively (mean difference −5.3, 95% CI −13.7 to −3.1; p=0.16). The disease management group had fewer per-protocol acute care hospitalisation days per year (p=0.047), a lower BODE index (p=0.01) and a lower mortality rate (1.9%versus14.2%; p<0.001), with no difference in exacerbation frequency. Patient profiles and hospitalisation practices varied substantially across countries.The COMET disease management intervention did not significantly reduce unplanned all-cause hospitalisation days, but reduced acute care hospitalisation days and mortality in severe COPD patients.
American journal of respiratory and critical care medicine · 2017
Abstract Rationale During noninvasive ventilation (NIV) for chronic obstructive pulmonary disease (COPD) exacerbations, helium/oxygen (heliox) reduces the work of breathing and hypercapnia more than air/O2, but its impact on clinical outcomes remains unknown. Objectives To determine whether continuous administration of heliox for 72 hours, during and in-between NIV sessions, was superior to air/O2 in reducing NIV failure (25–15%) in severe hypercapnic COPD exacerbations. Methods This was a prospective, randomized, open-label trial in 16 intensive care units (ICUs) and 6 countries. Inclusion criteria were COPD exacerbations with PaCO2 ≥ 45 mm Hg, pH ≤ 7.35, and at least one of the following: respiratory rate ≥ 25/min, PaO2 ≤ 50 mm Hg, and oxygen saturation (arterial [SaO2] or measured by pulse oximetry [SpO2]) ≤ 90%. A 6-month follow-up was performed. Measurements and Main Results The primary endpoint was NIV failure (intubation or death without intubation in the ICU). The secondary endpoints were physiological parameters, duration of ventilation, duration of ICU and hospital stay, 6-month recurrence, and rehospitalization rates. The trial was stopped prematurely (445 randomized patients) because of a low global failure rate (NIV failure: air/O2 14.5% [n = 32]; heliox 14.7% [n = 33]; P = 0.97, and time to NIV failure: heliox group 93 hours [n = 33], air/O2 group 52 hours [n = 32]; P = 0.12). Respiratory rate, pH, PaCO2, and encephalopathy score improved significantly faster with heliox. ICU stay was comparable between the groups. In patients intubated after NIV failed, patients on heliox had a shorter ventilation duration (7.4 ± 7.6 d vs. 13.6 ± 12.6 d; P = 0.02) and a shorter ICU stay (15.8 ± 10.9 d vs. 26.7 ± 21.0 d; P = 0.01). No difference was observed in ICU and 6-month mortality. Conclusions Heliox improves respiratory acidosis, encephalopathy, and the respiratory rate more quickly than air/O2 but does not prevent NIV failure. Overall, the rate of NIV failure was low. Clinical trial registered with www.clinicaltrials.gov (NCT 01155310).
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Respiratory medicine and research · 2023 · Journal Article
Pontier-Marchandise S, Texereau J, Prigent A, Gonzalez-Bermejo J, et al.
Medicine · 2023 · Journal Article
Nze Ossima A, Szfetel D, Denoyel B, Beloucif O, et al.
American journal of respiratory and critical care medicine · 2021 · Case Reports
Hua-Huy T, Lorut C, Aubourg F, Morbieu C, et al.
Chronic respiratory disease · 2019 · Journal Article
Arnal JM, Thevenin CP, Couzinou B, Texereau J, et al.
The European respiratory journal · 2018 · Journal Article
Kessler R, Casan-Clara P, Koehler D, Tognella S, et al.
International journal of chronic obstructive pulmonary disease · 2015 · Comparative Study
Häussermann S, Schulze A, Katz IM, Martin AR, et al.
Computer methods in biomechanics and biomedical engineering · 2015 · Journal Article
Gouinaud L, Katz I, Martin A, Hazebroucq J, et al.
Medical gas research · 2012 · Journal Article
Martin AR, Katz IM, Lipsitz Y, Terzibachi K, et al.
BMC pulmonary medicine · 2012 · Comparative Study
Martin AR, Katz IM, Jenöfi K, Caillibotte G, et al.
Intensive care medicine · 2011 · Journal Article
Roche-Campo F, Vignaux L, Galia F, Lyazidi A, et al.
Journal of aerosol medicine and pulmonary drug delivery · 2011 · Journal Article
Martin AR, Ang A, Katz IM, Häussermann S, et al.
Critical care medicine · 2004 · Journal Article
Texereau J, Pene F, Chiche JD, Rousseau C, et al.
Pulmonology · 2026 · Journal Article
Duval J, Texereau J, Bailly S, Pépin JL
JMIR research protocols · 2025 · Journal Article
Alami S, Schaller M, Blais S, Taupin H, et al.
Respiratory medicine and research · 2024 · Journal Article
Sabil A, Borel JC, Texereau J, Bailly S, et al.
Thorax · 2025 · Journal Article
Prigent A, Texereau JB, Schmitz C, Ropars C, et al.
American journal of respiratory and critical care medicine · 2017 · Clinical Trial, Phase III
Jolliet P, Ouanes-Besbes L, Abroug F, Ben Khelil J, et al.
International journal of chronic obstructive pulmonary disease · 2016 · Journal Article
Archivos de bronconeumologia · 2024 · Journal Article
Texereau J, Bailly S, Borel JC, Sabil A, et al.
Diabetes, obesity & metabolism · 2023 · Journal Article
Pépin JL, Bailly S, Texereau JB, Sonnet E, et al.
Thorax · 2025 · Journal Article
Prigent A, Texereau JB, Schmitz C, Ropars C, et al.
JMIR research protocols · 2025 · Journal Article
Alami S, Schaller M, Blais S, Taupin H, et al.
Journal of personalized medicine · 2022 · Journal Article
Hua-Huy T, Günther S, Lorut C, Subileau M, et al.
Respiration; international review of thoracic diseases · 2026 · Journal Article
Owadally Z, Guillemot M, Barthes R, Adler D, et al.
Respiratory research · 2025 · Clinical Trial
Prigent A, Texereau J, Bailly S, Gervais R, et al.
Sleep medicine reviews · 2024 · Journal Article
Gagnadoux F, Bequignon E, Prigent A, Micoulaud-Franchi JA, et al.
Diabetes, obesity & metabolism · 2023 · Journal Article
Pépin JL, Bailly S, Texereau JB, Sonnet E, et al.
Biomedical engineering online · 2016 · Clinical Trial
Leger D, Elbaz M, Piednoir B, Carron A, et al.
Bourbeau J, Casan P, Tognella S, Haidl P, et al.